Capital One Initiates Coverage On Protagonist Therapeutics with Overweight Rating
Portfolio Pulse from Benzinga Newsdesk
Capital One analyst Tim Chiang has initiated coverage on Protagonist Therapeutics (NASDAQ:PTGX) with an Overweight rating.
October 30, 2023 | 5:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics has been initiated with an Overweight rating by Capital One.
Analyst ratings often influence the short-term price of a stock. An Overweight rating suggests that the analyst believes the stock will outperform its industry in the near future. This could lead to increased investor interest and a potential rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100